Project Readiness & Execution Diagnostic.
For sponsors of complex, capital-intensive projects, the Diagnostic determines how prepared the current transaction is for serious institutional review, what evidence and conditions are missing, which workstreams must be resolved, and what should happen next. It establishes Baseline Execution State v1.0 and the Institutional Conditions Register.
Millentra currently delivers the Diagnostic as a methodology-led engagement with required human review. StructurAI™ is being developed to automate and scale the underlying evidence, rules, and tracking environment.
One of three grounded conclusions.
The project is sufficiently prepared to advance to the next defined institutional step, subject to stated conditions.
Material elements of the proposition, evidence base, sequencing, governance, or capital path require revision.
Critical evidence or conditions are not sufficiently developed to justify further institutional progression at this stage.
A Pause or Restructure conclusion is a valuable risk-management outcome, not a failed assessment.
Three entry points, one discipline.
Define the evidence, workstreams, dependencies, and institutional conditions the project must develop.
Assess bankability, organize the institutional proposition, and define the critical path toward formal diligence, approval, or financing.
Diagnose why a project has stalled, test the existing evidence and transaction structure, and identify what must be reworked.
The Diagnostic begins with the evidence currently available.
Missing evidence is itself recorded as a finding. Representative evidence categories:
- Project identity, stage, ownership, and site control
- Technical studies, design basis, delivery strategy, and operating assumptions
- Permits, regulatory approvals, interconnection, and jurisdictional requirements
- Offtake, revenue model, counterparty evidence, and commercial agreements
- Financial model, sources and uses, funding plan, and indicative capital structure
- Sponsor governance, SPV structure, decision rights, and key counterparties
- ESG, environmental, social, carbon, and institutional-framework evidence
- Existing legal, engineering, insurance, market, and third-party diligence
What the methodology assesses.
The six dimensions are published at this level only. Numerical weights, sub-weights, thresholds, decision trees, and internal rules are not published.
Two deliverables, one governed record.
- Executive conclusion and current readiness position
- Evidence-linked findings
- Bankability and institutional-readiness assessment
- Material risks and outstanding conditions
- Indicative capital-structure scenarios for human review
- Scope, assumptions, evidence cutoff, and limitations
- Prioritized gaps and distribution-gating conditions
- Responsible workstream for each gap
- Owners, dependencies, milestones, and target dates
- Critical path and expected sequencing
- Completion evidence required to close each condition
- Explainable readiness updates as work progresses
Diagnostics and any subsequent governed-resolution engagement are undertaken as paid, fixed-fee institutional engagements. Scope, timetable and fees are confirmed following an initial review of the project, available evidence and required workstreams.
Five steps from scope to coordination.
Millentra assesses the completeness and strength of available evidence against its configured institutional methodology. It does not independently certify engineering performance, legal compliance, ESG eligibility, creditworthiness, or financing availability. Material findings remain subject to specialist validation and institutional decision-making.
Frequently asked questions.
What does "institutional readiness" mean?
Institutional readiness describes the extent to which a project's evidence, transaction structure, governance, risk allocation, and required workstreams are sufficiently developed for serious review by investors, lenders, or strategic partners. It is not a financing approval or guarantee.
How is this different from technical due diligence?
Technical due diligence evaluates whether an asset can be designed, built, and operated as represented. Millentra connects technical evidence with commercial, financial, governance, ESG, regulatory, and execution conditions to identify what is preventing institutional progression and what must happen next.
Does Millentra replace my existing advisers?
No. Millentra can work with the sponsor's existing advisers. It identifies and structures the required workstreams, records ownership and dependencies, and coordinates status. Specialist conclusions and professional opinions remain with the appropriately qualified provider.
What evidence is required to begin?
The Diagnostic begins with the best evidence currently available. Typical inputs include site and technical materials, permits, interconnection and infrastructure evidence, offtake and commercial documents, the financial model, governance and SPV materials, ESG and regulatory evidence, and existing third-party diligence. Missing material is recorded and prioritized rather than concealed.
Can third-party engineering or power studies be incorporated?
Yes. Engineering studies, power-flow reports, permitting analyses, environmental reports, legal reviews, and other third-party materials can be recorded as identified evidence and linked to the findings or conditions they support. Millentra does not independently certify the underlying accuracy of those materials.
What happens after gaps are identified?
Gaps are prioritized, mapped to responsible workstreams, sequenced by dependency and critical path, and assigned completion evidence. The sponsor selects its advisers or specialists. Millentra can coordinate and track agreed workstreams and update readiness after relevant evidence is reviewed.
How are changes explained?
Each material update should state what changed, which evidence or decision caused the change, which condition closed or reopened, and the effect on readiness, risk, and critical path.
Does the Diagnostic recommend investors or guarantee capital?
No. The Diagnostic does not guarantee financing or provide securities brokerage. It structures the project's evidence, institutional conditions, and execution path for independent consideration by investors, lenders, and strategic partners.
What does the sponsor receive?
The sponsor receives a human-reviewed Structured Transaction Brief and Execution Roadmap covering current readiness, evidence-linked findings, prioritized conditions, responsible workstreams, dependencies, critical path, and practical next actions.
Can early-stage or stalled projects be assessed?
Yes. The scope and output are configured to the decision point. Early-stage projects receive a readiness roadmap, pre-financing projects receive an integrated assessment and execution plan, and stalled projects receive a diagnosis of the proposition and required restructuring.
Can Millentra deliver the Diagnostic before the StructurAI™ MVP is live?
Yes. Millentra currently delivers the Diagnostic as a methodology-led engagement with required human review. The StructurAI™ MVP is being developed to automate and scale evidence organization, structured assessment, workstream tracking, and versioned readiness updates.
What happens after the Diagnostic?
The Diagnostic establishes Baseline Execution State v1.0 and the Institutional Conditions Register. Where continued resolution is appropriate, the 90-Day Governed Resolution maintains the governed execution state as evidence is submitted, reviewed, accepted, rejected or reopened, with dependencies, critical paths, readiness and capital-path implications updated through versioned management decision records. It is not a guarantee that every condition will be resolved, or that financing, FID or any other approval will be obtained within that period.
Understand what is preventing institutional progression, and what must happen next.
This site sets no advertising or tracking cookies. Strictly necessary storage keeps the site working, and cookieless analytics measures aggregate usage without storing anything on your device. See our Cookie Notice.